Aelis Farma SA (EPA:AELIS)

Market Cap	13.07M -14.6%
Revenue (ttm)	2.08M -62.5%
Net Income	-6.43M
EPS	-0.47
Shares Out	13.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	571
Open	0.9700
Previous Close	0.9610
Day's Range	0.9610 - 0.9700
52-Week Range	0.6720 - 2.3000
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive imp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS

Financial Performance

In 2025, Aelis Farma's revenue was 2.08 million, a decrease of -62.53% compared to the previous year's 5.56 million. Losses were -6.43 million, -13.71% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error